(HealthDay)—The U.S. Food and Drug Administration says it has expanded approval for Blincyto (blinatumomab) to include adults and children with B-cell precursor acute lymphoblastic leukemia who are in remission but who ...
Mar 30, 2018
0
1
An international group of researchers led by Prof. Jan Cools of the VIB-KU Leuven Center for Cancer Biology have made a breakthrough in understanding the development of acute lymphoblastic leukemia, an aggressive cancer of ...
Mar 20, 2018
0
6
Last year, the Food and Drug Administration approved the first cellular immunotherapies to treat cancer. These therapies involve collecting a patient's own immune cells—called T cells—and supercharging them to home in ...
Mar 6, 2018
0
18
Researchers at the Stanford University School of Medicine have developed a technique that allowed them to determine at diagnosis whether children with acute lymphoblastic leukemia would relapse following treatment.
Mar 5, 2018
0
39
A study at Children's Hospital Los Angeles is shedding new light on the best therapeutic approach for a rare and aggressive leukemia called mixed phenotype acute leukemia (MPAL).
Feb 27, 2018
0
45
Imagine a drug that, a month after a single intravenous dose, wipes out all evidence of leukemia in 80 percent of deathly ill children who receive it.
Feb 8, 2018
0
20
Results of the global, multicenter, pivotal phase 2 study that led to the first FDA approval of a gene therapy/cell therapy approach known as CAR T-cell therapy, were published today in the New England Journal of Medicine. ...
Feb 1, 2018
0
255
Researchers from the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, selected to estimate the cost-effectiveness of the newly approved CAR-T therapies, have found the clinical benefit may justify ...
Dec 20, 2017
0
2
Let's start with the good news. Childhood cancer is rare, and success rates for recovery are high. According to the American Cancer Society, childhood cancers make up less than 1 percent of all cancers diagnosed each year. ...
Dec 8, 2017
0
0
St. Jude Children's Research Hospital scientists have evidence that an anti-malaria drug sensitizes a high-risk subtype of acute lymphoblastic leukemia (ALL) to treatment with a promising class of targeted drugs, raising ...
Dec 4, 2017
0
0
